Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; indigo carmine; lactose monohydrate; erythrosine; sodium lauryl sulfate; titanium dioxide; maize starch; gelatin; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; industrial methylated spirit; dimeticone 1510; lecithin - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extens

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - fluconazole - solution for infusion - fluconazole 2 mg/ml - antimycotics for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 100mg;   - capsule - 100 mg - active: fluconazole 100mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 200mg;   - capsule - 200 mg - active: fluconazole 200mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 50mg;   - capsule - 50 mg - active: fluconazole 50mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - fluconazole -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - fluconazole -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - fluconazole -